

chain nodes :

6 8

ring nodes :

1 2 3 4 5

chain bonds :

3-8 5-6

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 3-4 3-8 4-5 5-6

exact bonds :

2-3

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS8:Atom

Generic attributes :

8:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 8: Limited

O,O0



S,S0

C,C4

N,N2

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10827294.str



chain nodes :

6 8

ring nodes :

1 2 3 4 5

chain bonds :

3-8 5-6

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 3-4 3-8 4-5 5-6

exact bonds :

2-3

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:Atom

Generic attributes :

8:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 8: Limited

C,C3-5

N,N1-3

O,O0


S,S0

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:41:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7899 TO ITERATE

25.3% PROCESSED 2000 ITERATIONS

14 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*



PROJECTED ITERATIONS: 152653 TO 163307

PROJECTED ANSWERS: 659 TO 1551

L2 14 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10827294 (a).str



chain nodes :

6 8

ring nodes :

1 2 3 4 5

chain bonds :

3-8 5-6

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 3-4 3-8 4-5 5-6

exact bonds :

2-3



isolated ring systems :  
containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:Atom

Generic attributes :

8:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 8: Limited

O,O0

S,S0

C,C4


N,N2

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 14:44:14 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7899 TO ITERATE

25.3% PROCESSED 2000 ITERATIONS

10. ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*\*COMPLETE\*\*

PROJECTED ITERATIONS: 152653 TO 163307

PROJECTED ANSWERS: 412 TO 1166

10/827,294

L4 10 SEA SSS SAM L3

=> => s 13 sss ful

FULL SEARCH INITIATED 14:44:50 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 156192 TO ITERATE

100.0% PROCESSED 156192 ITERATIONS

724 ANSWERS

SEARCH TIME: 00.00.05

L5 724 SEA SSS FUL L3

=> => s 15

L6 9 L5

=> d 16 1-9 bib,ab,hitstr

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1193341 CAPLUS  
 DN 143:460148  
 TI Preparation of 4-[2-(cycloalkylamino)pyrimidin-4-yl]-3-phenylimidazolin-2-one derivatives as p38 MAP-kinase inhibitors for the treatment of inflammatory diseases  
 IN Kubo, Akira; Nakane, Tetsu; Nakajima, Tatsuo; Murakami, Takanori; Miyoshi, Hidetaka; Ogasawara, Akihito  
 PA Tanabe Seiyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Common Inu*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105790	A1	20051110	WO 2005-JP8564	20050428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005238390	A1	20051110	AU 2005-238390	20050428
CA 2563042	A1	20051110	CA 2005-2563042	20050428
EP 1740578	A1	20070110	EP 2005-738662	20050428
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI JP 2004-133204	A	20040428		
US 2004-566089P	P	20040429		
JP 2005-7832	A	20050114		
WO 2005-JP8564	W	20050428		

OS MARPAT 143:460148

AB The invention provides novel heterocyclic compds. I [wherein: R1 is a halogen, nitro, alkyl, etc.; p is 1 or 2; A is 2-oxo-4-imidazolin-3,4-diyl, etc.; X is CH or N; Z is O, NR2; R2 is H, alkyl, etc.; B is cycloalkyl or monocyclic saturated heterocyclic group; Y is single bond, CO, SO2; and E is an aryl or heterocyclic group; or a pharmaceutically acceptable salt thereof], which are useful as p38 MAP kinase inhibitors. Approx. 135 compds. I were prepared, as well as some intermediates. For instance, reaction of sulfoxide II with the corresponding trans-isomeric cyclohexylamine derivative at 90° in dioxane for 5 days gave invention compound III, isolated as the monohydrochloride. In an in-vivo test for inhibition of LPS-induced TNF- $\alpha$  production in rats, invention compound IV.HCl gave 100% inhibition at 5 mg/kg orally.

IT 869220-86-0P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[(4-succinimidocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-87-1P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[(4-(2-oxopyrrolidino)cyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869220-88-2P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[(4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one

869220-89-3P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(2-oxotetrahydrooxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869220-90-6P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxotetrahydroimidazol-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869220-91-7P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869220-92-8P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869220-93-9P, trans-3-(4-Fluorophenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-94-0P, trans-3-(4-Fluorophenyl)-1-(3-hydroxy-3-methylbutyl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-95-1P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-96-2P, trans-3-(4-Fluorophenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-97-3P, trans-3-(4-Fluorophenyl)-1-(3-hydroxy-3-methylbutyl)-4-[2-[[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-98-4P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869220-99-5P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-00-1P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-01-2P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(succinimidocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-02-3P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-03-4P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxotetrahydrooxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-04-5P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(pyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-05-6P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(pyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-06-7P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(pyrrol-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-07-8P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(pyrrol-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-08-9P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-09-0P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-10-3P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(2-oxotetrahydrooxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-11-4P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[[4-(2-

oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-12-5P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-13-6P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[4-(2-oxotetrahydrooxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-14-7P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-succinimidocyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-15-8P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(pyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-16-9P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[4-(pyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-17-0P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-18-1P, trans-3-(4-Fluorophenyl)-1-cyclobutyl-4-[2-[4-(succinimidocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-19-2P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-20-5P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-21-6P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(2-oxotetrahydro-1,3-oxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-22-7P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(2-oxotetrahydro-1,3-oxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-23-8P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(2-oxopyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-24-9P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(2-oxopyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-25-0P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-26-1P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one dihydrochloride 869221-27-2P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[4-(2,6-dioxo-4,4-dimethyltetrahydropiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-28-3P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[4-(2,6-dioxo-4,4-dimethyltetrahydropiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-29-4P, trans-3-(4-Fluorophenyl)-1-cyclopentyl-4-[2-[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-30-7P, trans-3-(4-Fluorophenyl)-1-cyclohexyl-4-[2-[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-31-8P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[4-(2,5-dioxo-3,3-dimethylpyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-32-9P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[4-(2,5-dioxo-3,3-

dimethylpyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-33-0P,  
trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2,5-dioxo-3,3-dimethylpyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-34-1P,  
3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,3,5-trimethylpyrazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-35-2P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(1,2-dimethylimidazol-5-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-36-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-37-4P,  
3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(phenylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-38-5P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(naphthalen-2-yl)sulfonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-39-6P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-[(pyridin-2-yl)carbonyl]piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-40-9P,  
, cis-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-41-0P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-42-1P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylsulfonyl)piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-43-2P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-acetylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-44-3P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-45-4P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-ethylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-46-5P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-47-6P,  
trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-48-7P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-49-8P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869221-50-1P, cis-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-51-2P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-52-3P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-(tert-butoxycarbonyl)piperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-53-4P, cis-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-54-5P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one

869221-55-6P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-56-7P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxopiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-57-8P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-58-9P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-59-0P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-60-3P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-61-4P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-62-5P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-63-6P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(pyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-64-7P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(2-oxopyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-65-8P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-66-9P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(2-oxo-1,3-oxazolidin-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-67-0P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(piperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-68-1P, trans-3-(3-Methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(4-acetylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-69-2P, trans-1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-70-5P, trans-5-Cyano-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-71-6P, trans-5-(Aminomethyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-72-7P, trans-5-Cyano-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-73-8P, trans-5-Cyano-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-74-9P, trans-5-Cyano-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-75-0P, trans-5-(Aminomethyl)-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-76-1P, trans-5-Cyano-3-(3-methylphenyl)-1-ethyl-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-77-2P, trans-5-Cyano-3-(3-methylphenyl)-1-ethyl-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-

imidazol-2-one 869221-78-3P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-79-4P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-80-7P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(hexahydroazepin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-81-8P, trans-3-(3-Chlorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-82-9P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-83-0P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-84-1P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-acetylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-85-2P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[4-(methylsulfonyl)piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-86-3P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[4-(methoxycarbonyl)piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-87-4P, trans-5-Methyl-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-88-5P, trans-1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-89-6P, trans-1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-90-9P, trans-1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-91-0P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-92-1P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-93-2P, trans-5-Methyl-3-(3-methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-94-3P, trans-3-(3-Methylphenyl)-5-methyl-1-isopropyl-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-95-4P, trans-3-(3-Methylphenyl)-5-methyl-1-isopropyl-4-[2-[[4-(3-oxo-4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-96-5P, trans-3-(3-Methylphenyl)-5-methyl-1-isopropyl-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-97-6P, trans-3-(3-Methylphenyl)-5-methyl-1-isopropyl-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-98-7P, trans-3-(3-Methylphenyl)-5-methyl-1-isopropyl-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869221-99-8P, trans-3-(4-Fluorophenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-00-4P, trans-3-(4-Fluorophenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-



dihydro-2H-imidazol-2-one 869222-01-5P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-02-6P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-03-7P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-04-8P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-05-9P  
 , trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(3-oxopiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-06-0P, trans-5-Methyl-3-(3-methylphenyl)-1-isopropyl-4-[2-[[4-(1,1-dioxotetrahydro-1,2-thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-07-1P, trans-5-Methyl-3-(3-methylphenyl)-1-isopropyl-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-08-2P, trans-3-(4-Fluorophenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(morpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-09-3P, trans-5-Methyl-3-(3-methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-acetylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-10-6P, trans-5-Methyl-3-(3-methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[4-(methylsulfonyl)piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-11-7P, trans-5-Methyl-3-(3-methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[4-(methoxycarbonyl)piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-12-8P, trans-3-(4-Fluorophenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxopyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-13-9P, trans-3-(4-Fluorophenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxo-1,3-oxazolidin-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-14-0P, trans-5-Methyl-3-(3-methylphenyl)-1-isopropyl-4-[2-[[4-(2-oxopyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-15-1P, trans-5-Methyl-3-(3-methylphenyl)-1-isopropyl-4-[2-[[4-(2-oxo-1,3-oxazolidin-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-16-2P, trans-3-(3-Methylphenyl)-5-methyl-1-(tetrahydropyran-4-yl)-4-[2-[[4-(piperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-17-3P, trans-5-Methyl-3-(3-methylphenyl)-1-(2-hydroxy-2-methylpropyl)-4-[2-[[4-(3-oxomorpholin-4-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-18-4P, trans-5-Methyl-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-19-5P, trans-5-Methyl-3-(4-fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(4-methylpiperazin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-20-8P, trans-3-(4-Fluorophenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-(2-oxopiperidin-1-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-21-9P, trans-3-(4-Fluorophenyl)-1-isobutyl-4-[2-[[4-(succinimidocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-22-0P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(2-oxopyrrolidino)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869222-23-1P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(1,1-dioxotetrahydro-1,2-


thiazol-2-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869222-24-2P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-(2-oxotetrahydrooxazol-3-yl)cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride 869222-25-3P, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[1-(thien-2-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one monohydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(cycloalkylamino)pyrimidinyl]phenylimidazol inone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)

RN 869220-86-0 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-87-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-88-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-89-3 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-90-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(2-oxo-1-imidazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-91-7 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 869220-92-8 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)



RN 869220-93-9 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-94-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-95-1 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-96-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869220-97-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869220-98-4 CAPLUS

CN 3-Morpholinone, 4-[[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869220-99-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-4-[[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



Relative stereochemistry.




● 2 HCl

RN 869221-00-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-  
[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl


RN 869221-01-2 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-  
methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-,

10/827,294

monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-02-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-03-4 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-04-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-  
[[trans-4-(1-pyrrolidinyl) cyclohexyl] amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-05-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-4-[2-  
[[trans-4-(1-pyrrolidinyl) cyclohexyl] amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 869221-06-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[trans-4-(1H-pyrrol-1-yl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-07-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-4-[2-[[trans-4-(1H-pyrrol-1-yl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-08-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-4-[2-  
[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-09-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-  
isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-  
dihydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 869221-10-3 CAPLUS  
 CN 2-Oxazolidinone, 3-[[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 869221-11-4 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-12-5 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclobutyl-4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-13-6 CAPLUS

CN 2-Oxazolidinone, 3-[[trans-4-[[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-14-7 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 869221-15-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(1-(2,5-pyrrolidinedione)cyclohexyl]amino)-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-




10/827,294

, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 869221-16-9 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[[trans-4-(1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 869221-17-0 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 869221-18-1 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-19-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-20-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-21-6 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[2,3-dihydro-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-22-7 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[3-(3-chlorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-23-8 CAPLUS.

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-24-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869221-25-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● 2 HCl


RN 869221-26-1 CAPLUS

10/827,294

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME).

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 869221-27-2 CAPLUS

CN 2,6-Piperidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-4,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869221-28-3 .CAPLUS

CN 2,6-Piperidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-4,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






● HCl

RN 869221-29-4 CAPLUS  
CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 869221-30-7 CAPLUS  
CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-31-8 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-3,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-32-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-3,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-33-0 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-3,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 869221-34-1 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 869221-35-2 CAPLUS


CN 4-Piperidinamine, 1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 869221-36-3 CAPLUS


CN 4-Piperidinamine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 869221-37-4 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 869221-38-5 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(2-naphthalenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 869221-39-6 CAPLUS

CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(2-pyridinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 869221-40-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-41-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-(1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-42-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-[4-(methylsulfonyl)-1-piperazinyl]cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-43-2 CAPLUS

CN Piperazine, 1-acetyl-4-[trans-4-[[4-[2,3-dihydro-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869221-44-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 869221-45-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(4-ethyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-46-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-47-6 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869221-48-7 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[2,3-dihydro-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-49-8 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[3-(3-chlorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-50-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[[cis-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-51-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-52-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-53-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-54-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-[(2S)-2-hydroxymethyl-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869221-55-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-hydroxy-1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-56-7 CAPLUS

CN Piperazinone, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-57-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-58-9 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-59-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-4-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869221-60-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-4-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 869221-61-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-62-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-methyl-1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-63-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-4-[2-[[trans-4-(1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-64-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-4-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-65-8 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-66-9 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-2-sulfinyl-1,1-dioxo- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-67-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-4-[2-[[trans-4-(1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-68-1 CAPLUS

CN Piperazine, 1-acetyl-4-[trans-4-[[4-[2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-69-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-5-methyl-4-[2-  
[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 869221-70-5 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-5-[2-[[trans-4-  
(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-2-oxo-3-(tetrahydro-2H-  
pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-71-6 CAPLUS

CN 2H-Imidazol-2-one, 4-(aminomethyl)-1-(4-fluorophenyl)-1,3-dihydro-5-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-72-7 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-5-[2-[[trans-4-(4-hydroxy-1-piperidiny)lcyclohexyl]amino]-4-pyrimidinyl]-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-73-8 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-5-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-2-oxo-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869221-74-9 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-2-oxo-5-[2-[[trans-4-(3-oxo-4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-75-0 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[5-(aminomethyl)-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869221-76-1 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 3-ethyl-2,3-dihydro-1-(3-methylphenyl)-5-[2-[[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 869221-77-2 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 3-ethyl-2,3-dihydro-1-(3-methylphenyl)-2-oxo-5-[2-[[trans-4-(3-oxo-4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-78-3 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[trans-4-(4-hydroxy-1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-79-4 CAPLUS

CN Piperazinone, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-80-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-4-[2-[[trans-4-(hexahydro-1H-azepin-1-yl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-81-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-82-9 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869221-83-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-3-(3-methylphenyl)-4-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-84-1 CAPLUS

CN Piperazine, 1-acetyl-4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-85-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-[4-(methylsulfonyl)-1-piperazinyl]cyclohexyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-86-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-87-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-5-methyl-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-88-5 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-5-methyl-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-89-6 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(4-hydroxy-1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-5-methyl- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 869221-90-9 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869221-91-0 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[2,3-dihydro-5-methyl-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869221-92-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-1-(3-methylphenyl)-5-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 869221-93-2 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-5-methyl-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-94-3 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[2,3-dihydro-5-methyl-1-(1-methylethyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-1-methylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-95-4 CAPLUS

CN Piperazinone, 4-[trans-4-[[4-[2,3-dihydro-5-methyl-1-(1-methylethyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-96-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-3-(1-methylethyl)-1-(3-methylphenyl)-5-[2-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-97-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-3-(1-methylethyl)-1-(3-methylphenyl)-5-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869221-98-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-5-methyl-1-(1-methylethyl)-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869221-99-8 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-5-methyl-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-00-4 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-4-methyl-5-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-01-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-1-(3-methylphenyl)-5-[2-[[trans-4-(1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-02-6 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-1-(3-methylphenyl)-5-[2-[[trans-4-(1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-03-7 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[trans-4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]cyclohexyl]amino]-4-pyrimidinyl]-5-methyl-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869222-04-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[trans-4-(4-hydroxy-1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-5-methyl-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-05-9 CAPLUS

CN Piperazinone, 4-[trans-4-[[4-[2,3-dihydro-5-methyl-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-06-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-1,3-dihydro-5-methyl-1-(1-methylethyl)-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-07-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-3-(1-methylethyl)-1-(3-methylphenyl)-5-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869222-08-2 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-4-methyl-5-[2-[[trans-4-(4-morpholinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 869222-09-3 CAPLUS

CN Piperazine, 1-acetyl-4-[trans-4-[[4-[2,3-dihydro-5-methyl-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-10-6 CAPLUS

CN Piperazine, 1-[trans-4-[[4-[2,3-dihydro-5-methyl-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-11-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[trans-4-[[4-[2,3-dihydro-5-methyl-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-12-8 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-4-methyl-5-[2-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-13-9 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-5-methyl-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-14-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-3-(1-methylethyl)-1-(3-methylphenyl)-5-[2-[[trans-4-(2-oxo-1-pyrrolidiny]cyclohexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-15-1 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[2,3-dihydro-5-methyl-1-(1-methylethyl)-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-16-2 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-1-(3-methylphenyl)-5-[2-[[trans-4-(1-piperidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-17-3 CAPLUS

CN 3-Morpholinone, 4-[trans-4-[[4-[2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-(3-methylphenyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-18-4 CAPLUS

CN Piperazinone, 4-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-5-methyl-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-19-5 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-4-methyl-5-[2-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-20-8 CAPLUS

CN 2-Piperidinone, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-21-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-22-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[[trans-4-(2-oxo-1-pyrrolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869222-23-1 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[[trans-4-(1,1-dioxido-2-isothiazolidinyl)cyclohexyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 869222-24-2 CAPLUS

CN 2-Oxazolidinone, 3-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.





● HCl

RN 869222-25-3 CAPLUS  
 CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(2-thienylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 869222-26-4P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-[(4-chlorobutyl)amino]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-27-5P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-[(3-chloropropyl)sulfonyl]amino]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-28-6P, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[[4-[(2-chloroethoxy)carbonyl]amino]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-29-7P, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[[4-[(2-nitrophenyl)sulfonyl]piperazin-1-yl]cyclohexyl]amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-32-2P, 5-Bromo-1-ethyl-3-(4-fluorophenyl)-4-[2-

(methylthio)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one  
 869222-33-3P, 1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-(methylthio)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one  
 869222-34-4P, 1-Ethyl-3-(4-fluorophenyl)-5-methyl-4-[2-(methylsulfinyl)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one  
 869222-35-5P, 5-Bromo-3-(4-fluorophenyl)-4-[2-(methylthio)pyrimidin-4-yl]-1-(tetrahydropyran-4-yl)-1,3-dihydro-2H-imidazol-2-one  
 869222-36-6P, 5-Cyano-3-(4-fluorophenyl)-4-[2-(methylthio)pyrimidin-4-yl]-1-(tetrahydropyran-4-yl)-1,3-dihydro-2H-imidazol-2-one  
 869222-37-7P, 5-Cyano-3-(4-fluorophenyl)-4-[2-(methylsulfinyl)pyrimidin-4-yl]-1-(tetrahydropyran-4-yl)-1,3-dihydro-2H-imidazol-2-one


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [(cycloalkylamino)pyrimidinyl]phenylimidazolinone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)

RN 869222-26-4 CAPLUS

CN Butanamide, 4-chloro-N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-27-5 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-28-6 CAPLUS

CN Carbamic acid, [trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-29-7 CAPLUS


CN Piperazine, 1-[trans-4-[[4-[2,3-dihydro-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-4-[(2-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 869222-32-2 CAPLUS

CN 2H-Imidazol-2-one, 4-bromo-3-ethyl-1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 869222-33-3 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-5-methyl-4-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 869222-34-4 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-5-methyl-4-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 869222-35-5 CAPLUS

CN 2H-Imidazol-2-one, 4-bromo-1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylthio)-4-pyrimidinyl]-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 869222-36-6 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-5-[2-(methylthio)-4-pyrimidinyl]-2-oxo-3-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 869222-37-7 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-(4-fluorophenyl)-2,3-dihydro-5-[2-(methylsulfinyl)-4-pyrimidinyl]-2-oxo-3-(tetrahydro-2H-pyran-4-yl)- (9CI)  
(CA INDEX NAME)




IT 685826-59-9, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-[(4-aminocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one  
775575-82-1, 3-(4-Fluorophenyl)-1-isopropyl-4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-38-8  
, 3-(4-Fluorophenyl)-1-isobutyl-4-[2-(methylsulfinyl)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-41-3, trans-3-(4-Fluorophenyl)-1-isopropyl-4-[2-(methylthio)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-43-5, 3-(4-Fluorophenyl)-4-[2-(methylthio)pyrimidin-4-yl]-1-(tetrahydropyran-4-yl)-1,3-dihydro-2H-imidazol-2-one 869222-44-6, 1-Ethyl-3-(4-fluorophenyl)-4-[2-(methylthio)pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one 869222-45-7, 3-(4-Fluorophenyl)-4-[2-(methylthio)pyrimidin-4-yl]-1-(tetrahydropyran-4-yl)-1,3-dihydro-2H-imidazol-2-one 869222-46-8  
, trans-3-(3-Methylphenyl)-1-(tetrahydropyran-4-yl)-4-[2-[(4-aminocyclohexyl)amino]pyrimidin-4-yl]-1,3-dihydro-2H-imidazol-2-one  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; preparation of [(cycloalkylamino)pyrimidinyl]phenylimida

zolinone derivs. as p38 MAP kinase inhibitors for the treatment of inflammatory diseases)

RN 685826-59-9 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 775575-82-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869222-38-8 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methylpropyl)-4-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869222-41-3 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 869222-43-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-(methylsulfinyl)-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)






RN 869222-44-6 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 869222-45-7 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-(methylthio)-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 869222-46-8 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-  
1,3-dihydro-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA  
INDEX NAME)

Relative stereochemistry.



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:857175 CAPLUS  
 DN 141:350167  
 TI Preparation of imidazolin-2-one derivatives as p38 MAP kinase inhibitors  
 IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;  
 Ogasawara, Akihito; Hiramatsu, Hajime; Nakajima, Tatsuo; Nakane, Tetsu  
 PA Japan  
 SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of Appl. No. PCT/JP02/10937.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204426	A1	20041014	US 2004-827294	20040420
	WO 2003035638	A1	20030501	WO 2002-JP10937	20021022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004201666	A1	20040513	AU 2004-201666	20040421
	WO 2004094404	A1	20041104	WO 2004-JP5716	20040421
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004339210	A	20041202	JP 2004-125060	20040421
	EP 1628968	A1	20060301	EP 2004-728708	20040421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	JP 2001-324029	A	20011022		
	JP 2002-263680	A	20020910		
	WO 2002-JP10937	A2	20021022		
	JP 2003-116076	A	20030421		
	AU 2002-363108	A3	20021022		
	WO 2004-JP5716	W	20040421		

OS MARPAT 141:350167

AB The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonyl, (un)substituted alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl),

PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts were prepared as p38 mitogen activation proteins (MAP) kinase inhibitors. Thus, reacting 2,2-diethoxy-2-(pyridin-4-yl)ethylamine (preparation given) with 4-fluorophenyl isocyanate afforded the imidazolinone II. The representative compds. I significantly reduced the production of TNF- $\alpha$  in mice in vivo.


IT 521092-07-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(MAP kinase inhibitor; preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 521092-07-9 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 521087-81-0P 521087-82-1P 521087-83-2P  
 521087-84-3P 521087-85-4P 521087-86-5P  
 521087-87-6P 521087-88-7P 521090-33-5P  
 521090-34-6P 521090-35-7P 521090-36-8P  
 521090-37-9P 521090-38-0P 521090-39-1P  
 521090-40-4P 521090-41-5P 521090-42-6P  
 521090-43-7P 521090-44-8P 521090-45-9P  
 521090-46-0P 521090-47-1P 521090-48-2P  
 521090-49-3P 521090-50-6P 521090-51-7P  
 521090-52-8P 521090-53-9P 521090-54-0P  
 521090-55-1P 521090-56-2P 521090-57-3P  
 521090-58-4P 521090-59-5P 521090-60-8P  
 521090-61-9P 521090-62-0P 521090-63-1P  
 521090-64-2P 521090-65-3P 521090-66-4P  
 521090-67-5P 521090-68-6P 521090-69-7P  
 521090-70-0P 521090-71-1P 521090-72-2P  
 521090-73-3P 521090-74-4P 521090-75-5P  
 521090-76-6P 521090-77-7P 521090-78-8P  
 521090-79-9P 521090-80-2P 521090-81-3P  
 521090-82-4P 521090-83-5P 521090-84-6P  
 521090-85-7P 521090-86-8P 521090-87-9P  
 521090-88-0P 521090-89-1P 521090-90-4P  
 521090-91-5P 521090-92-6P 521090-93-7P  
 521090-94-8P 521090-95-9P 521090-96-0P  
 521090-97-1P 521090-98-2P 521090-99-3P  
 521091-00-9P 521091-01-0P 521091-02-1P  
 521091-03-2P 521091-04-3P 521091-05-4P  
 521091-06-5P 521091-07-6P 521091-08-7P


521091-09-8P 521091-10-1P 521091-11-2P  
 521091-12-3P 521091-13-4P 521091-14-5P  
 521091-15-6P 521091-16-7P 521091-17-8P  
 521091-18-9P 521091-19-0P 521091-20-3P  
 521091-21-4P 521091-22-5P 521091-23-6P  
 521091-24-7P 521091-25-8P 521091-26-9P  
 521091-27-0P 521091-28-1P 521091-29-2P  
 521091-30-5P 521091-31-6P 521091-32-7P  
 521091-33-8P 521091-34-9P 521091-35-0P  
 521091-36-1P 521091-37-2P 521091-38-3P  
 521091-41-8P 521091-44-1P 521091-47-4P  
 521091-50-9P 521091-52-1P 521091-53-2P  
 521091-56-5P 521091-59-8P 521091-62-3P  
 521091-63-4P 521091-65-6P 521092-10-4P  
 521092-13-7P 521092-16-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MAP kinase inhibitor; preparation of imidazolinones as p38 MAP kinase inhibitors)


RN 521087-81-0 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-4-[2-[(2-furanylmethyl)amino]-4-pyrimidinyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521087-82-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521087-83-2 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521087-84-3 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(2-propenylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) : (CA INDEX NAME)




RN 521087-85-4 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[(2-hydroxybutyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521087-86-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(2-methoxyphenyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



RN 521087-87-6 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521087-88-7 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(1-methylethoxy)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)






RN 521090-33-5 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521090-34-6 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-35-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[(2-methoxyethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521090-36-8 CAPLUS

CN Benzonitrile, 2-[[4-[2-(cyclopropylamino)-4-pyrimidinyl]-3-[(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521090-37-9 CAPLUS

CN Benzonitrile, 2-[[4-[2-(butylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-38-0 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[(1-methylethyl)amino]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-39-1 CAPLUS

CN Benzonitrile, 2-[[4-[2-(ethylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-40-4 CAPLUS


CN Benzonitrile, 2-[[4-[2-[(cyclopropylmethyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-41-5 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-42-6 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 521090-43-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 521090-44-8 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 521090-45-9 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[ (1R)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521090-47-1 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[[1-(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-48-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)






RN 521090-49-3 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-50-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-1,1-dimethylethyl] ester (9CI) (CA INDEX NAME)



RN 521090-51-7 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 521090-52-8 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[4-methoxyphenyl]methyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 521090-53-9 CAPLUS

CN Benzonitrile, 2-[[4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-54-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-55-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-[(2-methoxyphenyl)methyl]- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 521090-56-2 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-57-3 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 521090-58-4 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521090-59-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 521090-60-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 521090-61-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-methyl-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-62-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-63-1 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-64-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 521090-65-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-66-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-67-5 CAPLUS

2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-, dihydrochloride (9CI). (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-68-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(cis-4-hydroxycyclohexyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1,4-dihydro-1,4-dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-69-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(cis-4-hydroxycyclohexyl)methyl]-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-70-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(trans-4-hydroxycyclohexyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-71-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(trans-4-hydroxycyclohexyl)methyl]-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-72-2 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-73-3 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-74-4 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-75-5 CAPLUS

CN Acetamide, N-[trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-76-6 CAPLUS

CN Acetamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-77-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●3 HCl

RN 521090-78-8 CAPLUS

CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

RN 521090-79-9 CAPLUS  
 CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
 1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, dihydrochloride  
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-80-2 CAPLUS  
 CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-,  
 dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.






● 2 HCl

RN 521090-81-3 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 3 HCl

RN 521090-82-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-[(cis-4-aminocyclohexyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-83-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-84-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-85-7 CAPLUS

CN 2H-Imidazol-2-one, 1-butyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-86-8 CAPLUS

CN 1H-Imidazole-1-acetonitrile, 3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-87-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-88-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(3-hydroxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-89-1 CAPLUS

CN 2H-Imidazol-2-one, 1-(cyclopropylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-90-4 CAPLUS


CN 2H-Imidazol-2-one, 1-(cyclobutylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 521090-91-5 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
 [(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

RN 521090-92-6 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 521090-93-7 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521090-94-8 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521090-95-9 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521090-96-0 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 521090-97-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI)  
(CA INDEX NAME)



RN 521090-98-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-99-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521091-00-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-01-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-3-(3-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-02-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-03-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-04-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-05-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-06-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-(3-methoxyphenyl)-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-07-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-08-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-(3-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-09-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-10-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-11-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-12-3 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-13-4 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(1-ethyl-3-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 521091-14-5 CAPLUS


CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 521091-15-6 CAPLUS


CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521091-16-7 CAPLUS

CN 2H-Imidazol-2-one, 1-(2,4-difluorophenyl)-1,3-dihydro-5-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-17-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-5-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 521091-18-9 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-methyl-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-19-0 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-20-3 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521091-21-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-22-5 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 521091-23-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-24-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-25-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-3-(3-methoxyphenyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-26-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-27-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 521091-28-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521091-29-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methoxyethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521091-30-5 CAPLUS

CN 1H-Imidazole-1-acetonitrile, 3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

INDEX NAME)




● HCl

RN 521091-31-6 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-32-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-33-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521091-34-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 521091-35-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-36-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[3-hydroxy-2,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-37-2 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (2S)-2-hydroxypropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 521091-38-3 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (2R)-2-hydroxypropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 521091-41-8 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-hydroxycyclohexyl)methyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-44-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 521091-47-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 521091-50-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[[[(1S)-1-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 521091-52-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1S,2S)-2-hydroxycyclopentyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 521091-53-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1S,2S)-2-hydroxycyclopentyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 521091-56-5 CAPLUS

CN Cyclohexanecarboxamide, 4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, monohydrochloride, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-59-8 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-62-3 CAPLUS

CN Carbamic acid, [trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-63-4. CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-65-6 CAPLUS  
 CN Carbamic acid, [trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 521092-10-4 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(methylthio)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)






RN 521092-13-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(methylsulfinyl)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521092-16-0 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT	774579-16-7P	774579-17-8P	774579-18-9P
	774579-19-0P	774579-20-3P	774579-21-4P
	774579-22-5P	774579-23-6P	774579-24-7P
	774579-25-8P	774579-26-9P	774579-27-0P
	774579-28-1P	774579-29-2P	774579-30-5P
	774579-31-6P	774579-32-7P	774579-33-8P
	774579-34-9P	774579-35-0P	774579-36-1P
	774579-37-2P	774579-38-3P	774579-39-4P
	774579-40-7P	774579-41-8P	774579-42-9P
	774579-43-0P	774579-44-1P	774579-45-2P
	774579-46-3P	774579-47-4P	774579-48-5P
	774579-49-6P	774579-50-9P	774579-51-0P
	774579-52-1P	774579-53-2P	774579-54-3P
	774579-55-4P	774579-56-5P	774579-57-6P
	774579-58-7P	774579-59-8P	774579-60-1P
	774579-61-2P	774579-62-3P	774579-63-4P
	774579-64-5P	774579-65-6P	774579-66-7P
	774579-67-8P	774579-68-9P	774579-69-0P
	774579-70-3P	774579-71-4P	774579-72-5P
	774579-73-6P	774579-74-7P	774579-75-8P
	774579-76-9P	774579-77-0P	774579-78-1P
	774579-79-2P	774579-80-5P	774579-81-6P
	774579-82-7P	774579-83-8P	774579-84-9P
	774579-85-0P	774579-86-1P	774579-87-2P
	774579-88-3P	774579-89-4P	774579-90-7P
	774579-91-8P	774579-92-9P	774579-93-0P
	774579-95-2P	774579-96-3P	774579-97-4P
	774579-98-5P	774579-99-6P	774580-00-6P
	774580-01-7P	774580-02-8P	774580-03-9P
	774580-04-0P	774580-05-1P	774580-06-2P
	774580-07-3P	774580-08-4P	774580-09-5P
	774580-10-8P	774580-11-9P	774580-12-0P
	774580-13-1P	774580-14-2P	774580-15-3P
	774580-16-4P	774580-17-5P	774580-18-6P
	774580-19-7P	774580-20-0P	774580-21-1P
	774580-22-2P	774580-23-3P	774580-24-4P
	774580-25-5P	774580-26-6P	774580-27-7P
	774580-28-8P	774580-29-9P	774580-30-2P
	774580-31-3P	774580-32-4P	774580-33-5P
	774580-34-6P	774580-35-7P	774580-36-8P
	774580-37-9P	774580-38-0P	774580-39-1P
	774580-40-4P	774580-41-5P	774580-42-6P
	774580-43-7P	774580-44-8P	774580-45-9P


774580-46-0P 774580-47-1P 774580-48-2P  
 774580-49-3P 774580-50-6P 774580-51-7P  
 774580-52-8P 774580-53-9P 774580-54-0P  
 774580-55-1P 774580-56-2P 774580-57-3P  
 774580-58-4P 774580-59-5P 774580-60-8P  
 774580-61-9P 774580-62-0P 774580-63-1P  
 774580-64-2P 774580-65-3P 774580-66-4P  
 774580-67-5P 774580-68-6P 774580-69-7P  
 774580-70-0P 774580-71-1P 774580-72-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolinones as p38 MAP kinase inhibitors)

RN 774579-16-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-17-8 CAPLUS

CN Cyclohexanecarboxamide, 4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-methyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774579-18-9 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(5-hydroxy-1,5-dimethylhexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-19-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(5-hydroxy-1,5-dimethylhexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-20-3 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-21-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-22-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-hydroxy-4-(1-methylethyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-23-6 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-24-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-25-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-hydroxy-4-(1-methylethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774579-26-9 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-27-0 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 774579-28-1 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-1,3-dimethylbutyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-29-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-1,3-dimethylbutyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-30-5 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-mercapto-2-methylpropyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-31-6 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[2-[[1,1-bis(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-32-7 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-2-methylpropyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-33-8 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 774579-34-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-1,2-dimethylpropyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-35-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-1,2-dimethylpropyl)-4-[2-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-36-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-1,2-dimethylpropyl)-4-[2-[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-37-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-1,2-dimethylpropyl)-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774579-38-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-hydroxy-1,1,2-trimethylpropyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-39-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(2-hydroxy-1,1,2-trimethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.



RN 774579-40-7 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-41-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-42-9 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-43-0 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 774579-44-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774579-45-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(3-hydroxy-3-methylbutyl)-4-[2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-46-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1R)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-47-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-48-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(3-hydroxy-3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774579-49-6 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-50-9 CAPLUS


CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-51-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-52-1 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-53-2 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-54-3 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[2-(cyclopropylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)



● HCl


RN 774579-55-4 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[2-[(2,2-dimethylpropyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)



● HCl


RN 774579-56-5 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-57-6 CAPLUS  
 CN Piperidine, 1-acetyl-4-[4-[2-[(2,2-dimethylpropyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-58-7 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-59-8 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 774579-60-1 CAPLUS  
 CN Piperidine, 1-acetyl-4-[4-[2-(cyclopropylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 774579-61-2 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1R)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-62-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-63-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774579-64-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 774579-65-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2S)-2-(hydroxyethyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-66-7 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-((tetrahydro-2H-pyran-4-yl)-4-[2-[(1,1-dimethylethyl)amino]-4-pyrimidinyl])-monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-67-8 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774579-68-9 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-  
 [(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-1H-imidazol-1-yl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-69-0 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[[(1S)-1-  
 (hydroxymethyl)propyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774579-70-3 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774579-71-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-

10/827,294

hydroxycyclohexyl) amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-72-5 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl) amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-,  
monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774579-73-6 CAPLUS

CN Piperidine, 4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774579-74-7 CAPLUS

CN Piperidine, 4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774579-75-8 CAPLUS

CN Piperidine, 4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-1-(methylsulfonyl)-,




monohydrochloride (9CI) (CA INDEX NAME)




RN 774579-76-9 CAPLUS

CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methanesulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 774579-77-0 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[1-(methanesulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-78-1 CAPLUS  
 CN 4-Piperidinamine, 1-acetyl-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride  
 (9CI) (CA INDEX NAME)



● HCl


RN 774579-79-2 CAPLUS  
 CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-80-5 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-81-6 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(propylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-82-7 CAPLUS


CN 4-Piperidinamine, 1-(butylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-83-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 2-methylpropyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-84-9 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(1-oxobutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-85-0 CAPLUS


CN 4-Piperidinamine, 1-acetyl-N-[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-86-1 CAPLUS


CN 4-Piperidinamine, N-[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 774579-87-2 CAPLUS


CN 4-Piperidinamine, N-[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(ethylsulfonyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 774579-88-3 CAPLUS


CN 1-Piperidinecarboxamide, N-ethyl-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-89-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-90-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-91-8 CAPLUS

CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 774579-92-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774579-93-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-95-2 CAPLUS

CN Piperidine, 4-[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[1-(2-hydroxy-1,2-dimethylpropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 774579-96-3 CAPLUS

CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774579-97-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-[(3R)-3-pyrrolidinylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774579-98-5 CAPLUS

CN 3-Pyrrolidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 774579-99-6 CAPLUS


CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-00-6 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-01-7 CAPLUS

CN 4-Piperidinamine, N-[4-[1-(cyclopropylmethyl)-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-02-8 CAPLUS


CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774580-03-9 CAPLUS


CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774580-04-0 CAPLUS

CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-05-1 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-06-2 CAPLUS  
 CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774580-07-3 CAPLUS  
 CN 4-Piperidinamine, 1-acetyl-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-08-4 CAPLUS  
 CN 4-Piperidinamine, 1-acetyl-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 774580-09-5 CAPLUS


CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(methoxymethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-10-8 CAPLUS


CN 4-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(methoxymethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-11-9 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-12-0 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-13-1 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(2-hydroxy-2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774580-14-2 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-15-3 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-16-4 CAPLUS


CN 4-Piperidinamine, N-[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-  
1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride

(9CI) (CA INDEX NAME)




● HCl

RN 774580-17-5 CAPLUS  
 CN 4-Piperidinamine, N-[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(ethylsulfonyl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)



● HCl


RN 774580-18-6 CAPLUS  
 CN 4-Piperidinamine, N-[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-19-7 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[[4-[1-cyclobutyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-20-0 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[[4-[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-21-1 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-, monohydrochloride  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774580-22-2 CAPLUS

CN 3-Piperidinamine, N-[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methanesulfonyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 774580-23-3 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(methoxymethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-24-4 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 774580-25-5 CAPLUS

CN 1-Piperidinesulfonamide, 4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-26-6 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-N-methyl-, monohydrochloride (9CI). (CA INDEX NAME)


Relative stereochemistry.



RN 774580-27-7 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774580-28-8 CAPLUS

CN Methanesulfonamide, N-ethyl-N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(3-hydroxy-3-methylbutyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 774580-29-9 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(3-amino-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 774580-30-2 CAPLUS


CN 2H-Imidazol-2-one, 4-[2-[(2-amino-2-methylpropyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 774580-31-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-32-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-cyclobutyl-3-(4-fluorophenyl)-1,3-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 · HCl

RN 774580-33-5 CAPLUS  
 CN Piperidine, 1-acetyl-4-[2,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-3-(3-methylphenyl)-2-oxo-1H-imidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-34-6 CAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774580-35-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774580-36-8 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-37-9 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-3-(3-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-38-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-39-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 774580-40-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-



methylcyclohexyl) amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-41-5 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl) amino]-4-pyrimidinyl]-1-(tetrahydro-2H-pyran-4-yl)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 774580-42-6 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-4-[2-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl) amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-43-7 CAPLUS


CN Acetamide, N-[2-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-1,1-dimethylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-44-8 CAPLUS


CN Methanesulfonamide, N-[2-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-1,1-dimethylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-45-9 CAPLUS


CN Acetamide; N-[3-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-2,2-dimethylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-46-0 CAPLUS

CN Methanesulfonamide, N-[3-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-2,2-dimethylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-47-1 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-48-2 CAPLUS


CN 4-Piperidinamine, N-[4-[1-cyclopentyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-  
1H-imidazol-4-yl]-2-pyrimidinyl]-1-(ethylsulfonyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)



● HCl

RN 774580-49-3 CAPLUS


CN 4-Piperidinamine, N-[4-[1-cyclopentyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-50-6 CAPLUS


CN 4-Piperidinamine, N-[4-[1-cyclopentyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methanesulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-51-7 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 774580-52-8 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-53-9 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-  
 [(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 774580-54-0 CAPLUS


CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2S)-2-hydroxy-1,1-dimethylethyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-55-1 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 774580-56-2 CAPLUS

CN 2H-Imidazol-2-one, 1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride  
(9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 774580-57-3 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-cyclopentyl-3-(4-fluorophenyl)-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 774580-58-4 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 774580-59-5 CAPLUS  
 CN 4-Piperidinamine, N-[4-[1-cyclohexyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(ethylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-60-8 CAPLUS  
 CN 4-Piperidinamine, N-[4-[1-cyclohexyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-61-9 CAPLUS  
 CN 4-Piperidinamine, N-[4-[1-cyclohexyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methanesulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774580-62-0 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-63-1 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 774580-64-2 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 774580-65-3 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl


RN 774580-66-4 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride, (9CI)  
 (CA INDEX NAME)



● HCl

RN 774580-67-5 CAPLUS  
 CN 2H-Imidazol-2-one, 1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-68-6 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-cyclohexyl-3-(4-fluorophenyl)-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 774580-69-7 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-2,2-dimethylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-70-0 CAPLUS


CN Methanesulfonamide, N-[2-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-1,1-dimethylethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774580-71-1 CAPLUS

CN 4-Piperidinamine, N-[4-[2,3-dihydro-3-(3-methylphenyl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774580-72-2 CAPLUS

CN 4-Piperidinamine, N-[4-[3-(3-chlorophenyl)-2,3-dihydro-2-oxo-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-4-yl]-2-pyrimidinyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



10/827,294



● HCl

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:335096 CAPLUS  
 DN 138:353990  
 TI Preparation of 4-imidazolin-2-one derivatives as MAP kinase inhibitors  
 IN Kubo, Akira; Imashiro, Ritsuo; Sakurai, Hiroaki; Miyoshi, Hidetaka;  
Ogasawara, Akihito; Hiramatsu, Hajime  
 PA Tanabe Seiyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 137 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

*Appl PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035638	A1	20030501	WO 2002-JP10937	20021022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461100	A1	20030501	CA 2002-2461100	20021022
	EP 1439174	A1	20040721	EP 2002-802049	20021022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013465	A	20041109	BR 2002-13465	20021022
	CN 1571781	A	20050126	CN 2002-820837	20021022
	HU 200401949	A2	20050128	HU 2004-1949	20021022
	US 2004204426	A1	20041014	US 2004-827294	20040420
	NO 2004002010	A	20040709	NO 2004-2010	20040514
PRAI	JP 2001-324029	A	20011022		
	JP 2002-263680	A	20020910		
	WO 2002-JP10937	W	20021022		
	JP 2003-116076	A	20030421		


OS MARPAT 138:353990

AB The title compds. I [wherein G1 = (un)substituted alkyl or B-W; B = (un)substituted Ph, Naphthyl, aromatic heterocyclyl, or cycloalkyl; W = a single bond or (un)substituted alkylene; Q1 and Q2 = independently H, halo, or alkyl; n = 0-4; R1 = H, (un)substituted (cyclo)alkyl, Ph, or heterocyclyl; Z1-Z4 = independently CH or N with exclusions; G2 = H, NR3R4, OR5, SR5, COR6, CHR7R8, or heterocyclyl; R3-R8 = independently H, alkenyl, alkynyl, OH, alkoxy, alkoxyoxalyl, alkylsulfonyl, (un)substituted alkyl, amino, alkanoyl, carbamoyl, cycloalkyl, Ph, heterocyclyl(carbonyl), PhCO, or heterocyclyl-CO] and pharmaceutically acceptable salts are prepared as mitogen activation proteins (MAP) kinase inhibitors. For example, the compound II·HCl was prepared in a multi-step synthesis. II·HCl showed 69% inhibitory activity against TNF-α in rat in the amount of 1 mg/kg after 90 min.

IT 521092-07-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (MAP kinase inhibitor; preparation of imidazolinone derivs. as MAP kinase inhibitors)

RN 521092-07-9 CAPLUS  
CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 521087-81-0P 521087-82-1P 521087-83-2P  
521087-84-3P 521087-85-4P 521087-86-5P  
521087-87-6P 521087-88-7P 521090-33-5P  
521090-34-6P 521090-35-7P 521090-36-8P  
521090-37-9P 521090-38-0P 521090-39-1P  
521090-40-4P 521090-41-5P 521090-42-6P  
521090-43-7P 521090-44-8P 521090-45-9P  
521090-46-0P 521090-47-1P 521090-48-2P  
521090-49-3P 521090-50-6P 521090-51-7P  
521090-52-8P 521090-53-9P 521090-54-0P  
521090-55-1P 521090-56-2P 521090-57-3P  
521090-58-4P 521090-59-5P 521090-60-8P  
521090-61-9P 521090-62-0P 521090-63-1P  
521090-64-2P 521090-65-3P 521090-66-4P  
521090-67-5P 521090-68-6P 521090-69-7P  
521090-70-0P 521090-71-1P 521090-72-2P  
521090-73-3P 521090-74-4P 521090-75-5P  
521090-76-6P 521090-77-7P 521090-78-8P  
521090-79-9P 521090-80-2P 521090-81-3P  
521090-82-4P 521090-83-5P 521090-84-6P  
521090-85-7P 521090-86-8P 521090-87-9P  
521090-88-0P 521090-89-1P 521090-90-4P  
521090-91-5P 521090-92-6P 521090-93-7P  
521090-94-8P 521090-95-9P 521090-96-0P  
521090-97-1P 521090-98-2P 521090-99-3P  
521091-00-9P 521091-01-0P 521091-02-1P  
521091-03-2P 521091-04-3P 521091-05-4P  
521091-06-5P 521091-07-6P 521091-08-7P  
521091-09-8P 521091-10-1P 521091-11-2P  
521091-12-3P 521091-13-4P 521091-14-5P  
521091-15-6P 521091-16-7P 521091-17-8P  
521091-18-9P 521091-19-0P 521091-20-3P  
521091-21-4P 521091-22-5P 521091-23-6P  
521091-24-7P 521091-25-8P 521091-26-9P  
521091-27-0P 521091-28-1P 521091-29-2P  
521091-30-5P 521091-31-6P 521091-32-7P  
521091-33-8P 521091-34-9P 521091-35-0P  
521091-36-1P 521091-37-2P 521091-38-3P  
521091-41-8P 521091-44-1P 521091-47-4P  
521091-50-9P 521091-52-1P 521091-53-2P

521091-56-5P 521091-59-8P 521091-62-3P

521091-63-4P 521091-65-6P 521092-10-4P


521092-13-7P 521092-16-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(MAP kinase inhibitor; preparation of imidazolinone derivs. as MAP kinase  
inhibitors)


RN 521087-81-0 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-4-[2-[(2-furanylmethyl)amino]-4-  
pyrimidinyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX  
NAME)




RN 521087-82-1 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(3-  
methoxypropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521087-83-2 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
 (CA INDEX NAME)



RN 521087-84-3 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-(2-propenylamino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521087-85-4 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(4-hydroxybutyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521087-86-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(2-methoxyphenyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 521087-87-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME).




RN 521087-88-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(1-methylethoxy)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-33-5 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521090-34-6 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-35-7 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(2-methoxyethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)






RN 521090-36-8 CAPLUS

CN Benzonitrile, 2-[[4-[2-(cyclopropylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-37-9 CAPLUS

CN Benzonitrile, 2-[[4-[2-(butylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-38-0 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[(1-methylethyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)




RN 521090-39-1 CAPLUS

CN Benzonitrile, 2-[[4-[2-(ethylamino)-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-40-4 CAPLUS


CN Benzonitrile, 2-[[4-[2-[(cyclopropylmethyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-41-5 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-42-6 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 521090-43-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 521090-44-8 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[ (1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 521090-45-9 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[[ (1R)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 521090-46-0 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521090-47-1 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[[2-[[1-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[(phenylmethyl)-4-piperidinyl]amino]-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521090-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 521090-49-3 CAPLUS

CN Benzonitrile, 2-[[[3-(4-fluorophenyl)-2,3-dihydro-4-[[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 521090-50-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-[1-[(2-cyanophenyl)methyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 521090-51-7 CAPLUS

CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-2-oxo-4-[[2-((4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl)methyl]-1,1-dimethylethyl ester]-2-pyrimidinyl]amino)-4-pyrimidinyl]-1H-imidazol-1-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 521090-52-8 CAPLUS


CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521090-53-9 CAPLUS

CN Benzonitrile, 2-[[4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-54-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-55-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-56-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 521090-57-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 521090-58-4 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521090-59-5 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-1-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 521090-60-8 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)




● 2 HCl

RN 521090-61-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1-[(2-fluorophenyl)methyl]-1,3-dihydro-4-[2-[(trans-4-(hydroxycyclohexyl)amino)-4-pyrimidinyl]-1-methyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-62-0 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-63-1 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521090-64-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521090-65-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-66-4 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-67-5 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.






● 2 HCl

RN 521090-68-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(cis-4-hydroxycyclohexyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-69-7 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(cis-4-hydroxycyclohexyl)methyl]-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-70-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(trans-4-hydroxycyclohexyl)methyl]-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-71-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-[(trans-4-hydroxycyclohexyl)methyl]-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-72-2 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-73-3 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-74-4 CAPLUS

CN 2H-Imidazol-2-one, 1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 521090-75-5 CAPLUS

CN Acetamide, N-[trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-  
imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI):  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-76-6 CAPLUS

CN Acetamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-77-7 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-[(cis-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●3 HCl

RN 521090-78-8 CAPLUS

CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-79-9 CAPLUS

CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-4-[2-(2-methylpropyl)amino]-4-pyrimidinyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-80-2 CAPLUS

CN 2H-Imidazol-2-one, 1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-  
1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 521090-81-3 CAPLUS

CN 2H-Imidazol-2-one, 4-[2-[(trans-4-aminocyclohexyl)amino]-4-pyrimidinyl]-1-[(trans-4-aminocyclohexyl)methyl]-3-(4-fluorophenyl)-1,3-dihydro-,  
trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 3 HCl

RN 521090-82-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-[(cis-4-hydroxycyclohexyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-83-5 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 521090-84-6 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-propyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521090-85-7 CAPLUS  
 CN 2H-Imidazol-2-one, 1-butyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-86-8 CAPLUS

CN 1H-Imidazole-1-acetonitrile, 3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-2-oxo-, monohydrochloride (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-87-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-88-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(3-hydroxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521090-89-1 CAPLUS

CN 2H-Imidazol-2-one, 1-(cyclopropylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 521090-90-4 CAPLUS  
 CN 2H-Imidazol-2-one, 1-(cyclobutylmethyl)-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 521090-91-5 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521090-92-6 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 521090-93-7 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[[(2S)-2-hydroxy-1,1-dimethylethyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521090-94-8 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(hydroxymethyl)cyclopentyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 521090-95-9 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521090-96-0 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 521090-97-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1-(hydroxymethyl) cyclopentyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 521090-98-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521090-99-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(cis-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 521091-00-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 521091-01-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-3-(3-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-02-1 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-03-2 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-04-3 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-05-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-06-5 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-(3-methoxyphenyl)-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-07-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(3-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-08-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-(3-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-09-8 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-10-1 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-11-2 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-3-phenyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-12-3 CAPLUS  
 CN 2H-Imidazol-2-one, 1-ethyl-3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-13-4 CAPLUS


CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521091-14-5 CAPLUS


CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(trans-4-hydroxycyclohexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 521091-15-6 CAPLUS


CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-[(2-methylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-16-7 CAPLUS


CN 2H-Imidazol-2-one, 1-(2,4-difluorophenyl)-1,3-dihydro-5-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521091-17-8 CAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-5-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-1-phenyl- (9CI) (CA INDEX NAME)





RN 521091-18-9 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-methyl-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-19-0 CAPLUS


CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-20-3 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 521091-21-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-22-5 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 521091-23-6 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1-ethyl-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-24-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(3-fluorophenyl)-1,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-25-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-1,3-dihydro-3-(3-methoxyphenyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-26-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(2,4-difluorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 521091-27-0 CAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 521091-28-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-1-(methoxymethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 521091-29-2 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(2-methoxyethyl)-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-30-5 CAPLUS

CN 1H-Imidazole-1-acetonitrile, 3-(4-fluorophenyl)-2,3-dihydro-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521091-31-6 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-32-7 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521091-33-8 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 521091-34-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[cis-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-35-0 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[trans-4-(hydroxymethyl)cyclohexyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 521091-36-1 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)




● HCl

RN 521091-37-2 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (2S)-2-hydroxypropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl


RN 521091-38-3 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (2R)-2-hydroxypropyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 521091-41-8 CAPLUS  
 CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[ (1-hydroxycyclohexyl)methyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 521091-44-1 CAPLUS


CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 521091-47-4 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-(4-piperidinylamino)-4-pyrimidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 521091-50-9 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-1-(1-methylethyl)-4-[2-  
 [(1S)-1-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]-, dihydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 521091-52-1 CAPLUS

CN 2H-Imidazol-2-one, 3-(4-fluorophenyl)-1,3-dihydro-4-[2-[[1S,2S)-2-  
 hydroxycyclopentyl]amino]-4-pyrimidinyl]-1-(1-methylethyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 521091-53-2 CAPLUS

CN 2H-Imidazol-2-one, 1-ethyl-3-(4-fluorophenyl)-1,3-dihydro-4-[2-[(1S,2S)-2-hydroxycyclopentyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 521091-56-5 CAPLUS

CN Cyclohexanecarboxamide, 4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-59-8 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-62-3 CAPLUS

CN Carbamic acid, [trans-4-[[4-[3-(4-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-63-4 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521091-65-6 CAPLUS


CN Carbamic acid, [trans-4-[[4-[1-ethyl-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-4-yl]-2-pyrimidinyl]amino]cyclohexyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521092-10-4 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(methylthio)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 521092-13-7 CAPLUS  
 CN Benzonitrile, 2-[[3-(4-fluorophenyl)-2,3-dihydro-4-[2-(methylsulfinyl)-4-pyrimidinyl]-2-oxo-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 521092-16-0 CAPLUS

CN 2H-Imidazol-2-one, 1-(4-fluorophenyl)-1,3-dihydro-5-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 99


THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:845271 CAPLUS  
 DN 137:346175  
 TI Use of lipoxxygenase inhibitors for the treatment of acne  
 IN Zouboulis, Christos C.  
 PA Germany  
 SO Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

*Same as #5*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10121252	A1	20021107	DE 2001-10121252	20010430
	CA 2445634	A1	20021114	CA 2002-2445634	20020429
	WO 2002089791	A2	20021114	WO 2002-EP4715	20020429
	WO 2002089791	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002302587	A1	20021118	AU 2002-302587	20020429
	EP 1385505	A2	20040204	EP 2002-730223	20020429
	EP 1385505	B1	20060705		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004528360	T	20040916	JP 2002-586926	20020429
	AT 332129	T	20060715	AT 2002-730223	20020429
	US 2004259920	A1	20041223	US 2004-476405	20040802
PRAI	DE 2001-10121252	A	20010430		
	WO 2002-EP4715	W	20020429		
AB	The invention discloses the use of lipoxxygenase inhibitors for the treatment of acne, in particular inflammatory acne. The lipoxxygenase inhibitor can be used alone or into combination with other lipoxxygenase inhibitors or with further anti-acne agents in a suitable pharmaceutical composition, in particular via oral and/or local topical application.				
IT	187112-44-3, PD 145246				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(PD 145246; lipoxxygenase inhibitors for treatment of acne)				
RN	187112-44-3 CAPLUS				
CN	2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)				



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:754502 CAPLUS

DN 133:321880

TI Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor.

IN Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.

PA G.D. Searle and Co., USA

SO U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 489,472, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6136839	A	20001024	US 1996-661660	19960611
	CA 2224517	A1	19961227	CA 1996-2224517	19960611
	ES 2247604	T3	20060301	ES 1996-918465	19960611
PRAI	US 1995-489472	B2	19950612		

OS MARPAT 133:321880

AB A combination comprising a 5-lipoxygenase inhibitor and a cyclooxygenase-2 inhibitor selected from title compds. [I; A = pyrazolyl; R1 =  $\geq 1$  of (substituted) heterocyclyl, cycloalkyl, cycloalkenyl, aryl; R2 = Me, amino; R3 = H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, CO<sub>2</sub>H, cyanoalkyl, heterocyclyloxy, alkoxy, alkylthio, alkylcarbonyl, aryl, haloalkyl, etc.], is claimed. Thus, EtO<sub>2</sub>CCHF<sub>2</sub> in MeOCMe<sub>3</sub> was treated with NaOMe and then with 3-fluoro-4-methoxyacetophenone (preparation given) followed by 16 h stirring to give 96% 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione. This was refluxed 16 h with 4-sulfonamidophenylhydrazine hydrochloride in EtOH to give 87% 4-[5-(3-fluoro-4-methoxyphenyl)-3-difluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide (II). II with 6-[[3-fluoro-5-(3,4,5,6-tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-1H-quinazolin-2-one (III) at 30 mpk/day orally in mice in the collagen-induced arthritis screen reduced incidence of arthritis to 20% (vs. 100% for controls). A formulation containing II and III is given.


IT 187112-44-3, PD 145246

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor)

RN 187112-44-3 CAPLUS

CN 2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:562996 CAPLUS

DN 127:239123

TI Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors

IN Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

PA G.D. Searle and Co., USA; Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

SO PCT Int. Appl., 68 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729776	A1	19970821	WO 1997-US1558	19970212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2246265	A1	19970821	CA 1997-2246265	19970212
	AU 9718505	A	19970902	AU 1997-18505	19970212
	EP 888127	A1	19990107	EP 1997-904133	19970212
	EP 888127	B1	20011212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000504723	T	20000418	JP 1997-529363	19970212
	AT 210461	T	20011215	AT 1997-904133	19970212
	PT 888127	T	20020531	PT 1997-904133	19970212
	ES 2169351	T3	20020701	ES 1997-904133	19970212
	US 6376528	B1	20020423	US 1999-430072	19991018
	US 2002143033	A1	20021003	US 2002-98644	20020315
	US 7132441	B2	20061107		
PRAI	US 1996-600622	A1	19960213		
	WO 1997-US1558	W	19970212		
	US 1998-189463	B1	19981110		
	US 1999-430072	A3	19991018		
OS	MARPAT 127:239123				
AB	Treatment with a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases. 4-[5-(3-Fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide and N'-[3-[5-(4-fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N'-hydroxyurea were prepared and a combination of these 2 compds. showed a delay in rejection time of skin grafts while treatment alone of time of skin each of these compds. resulted in no prolongation of graft survival.				
IT	187112-44-3, PD-145246				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(cyclooxygenase-2 and 5-lipoxygenase inhibitor combinations with immunosuppressive effects)				
RN	187112-44-3 CAPLUS				
CN	2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)				



L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:174992 CAPLUS

DN 126:166479

TI Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders

IN Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2


*Same as #6*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9641626	A1	19961227	WO 1996-US10106	19960611
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2224517	A1	19961227	CA 1996-2224517	19960611
	AU 9661117	A	19970109	AU 1996-61117	19960611
	EP 833622	A1	19980408	EP 1996-918465	19960611
	EP 833622	B1	20050810		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 11507670	T	19990706	JP 1997-503273	19960611
	AT 301457	T	20050815	AT 1996-918465	19960611
	ES 2247604	T3	20060301	ES 1996-918465	19960611
PRAI	US 1995-489472	A	19950612		
	WO 1996-US10106	W	19960611		
OS	MARPAT 126:166479				
AB	Combinations of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor are described for treatment of inflammation and inflammation-related disorders. Preparation of e.g. 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is described., as are pharmaceutical formulations and activity against collagen-induced arthritis in mice.				
IT	187112-44-3, PD 145246				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)				
RN	187112-44-3 CAPLUS				
CN	2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)				




L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:788052 CAPLUS  
 DN 124:8742  
 TI Synthesis of pyrimidine analogs of 2,6-di-tert-butylphenol  
 antiinflammatory agents  
 AU Unangst, Paul C.; Connor, David T.; Kostlan, Catherine R.; Shrum, Gary P.;  
 Miller, Steven R.; Kanter, Gerald  
 CS Parke-Davis Pharmaceutical Research, Division Warner-Lambert Company, Ann  
 Arbor, MI, 48105, USA  
 SO Journal of Heterocyclic Chemistry (1995), 32(4), 1197-200  
 CODEN: JHTCAD; ISSN: 0022-152X  
 PB HeteroCorporation  
 DT Journal  
 LA English  
 OS CASREACT 124:8742  
 AB The preparation of pyrimidine analogs (e.g., I) of the 2,6-di-tert-butylphenol  
 antiinflammatory agents Prifelone (R-830), Tebufelone (NE-11740) and  
 Ym-13,162 is described: Grignard addition to the N-methoxy-N-methylamide  
 derived from 4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinecarboxylic  
 acid yielded a series of 2-pyrimidinyl ketones. Further elaboration of an  
 Et ketone and cyclization with Na cyanate gave a pyrimidinylimidazole.  
 IT 187112-44-3P.  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis of pyrimidine analogs of di-tert-butylphenol  
 antiinflammatory agents)  
 RN 187112-44-3 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-  
 1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)

same as #6



IT 171003-98-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis of pyrimidine analogs of di-tert-butylphenol  
 antiinflammatory agents)  
 RN 171003-98-8 CAPLUS  
 CN 2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl-, monomethanesulfonate (salt). (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 187112-44-3  
 CMF C16 H24 N4 O2


10/827,294



CM 2

CRN 75-75-2

CMF C H4 O3 S






L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1994:134509 CAPLUS  
 DN 120:134509  
 TI 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents  
 IN Connor, David T.; Kostlan, Catherine R.; Unangst, Paul C.  
 PA Warner-Lambert Co., USA  
 SO U.S., 5 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

*Same as before*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5240929	A	19930831	US 1992-924212	19920803
	US 5312821	A	19940517	US 1993-54382	19930428
	WO 9403448	A1	19940217	WO 1993-US7034	19930727
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 652874	A1	19950517	EP 1993-918407	19930727
	EP 652874	B1	20031105		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08500101	T	19960109	JP 1994-505384	19930727
	JP 3223190	B2	20011029		
	AU 672619	B2	19961010	AU 1993-47870	19930727
	AU 9347870	A	19940303		
	AT 253571	T	20031115	AT 1993-918407	19930727
	CA 2139731	C	20040113	CA 1993-2139731	19930727
	PT 652874	T	20040331	PT 1993-918407	19930727
	ES 2206460	T3	20040516	ES 1993-918407	19930727
PRAI	US 1992-924212	A3	19920803		
	WO 1993-US7034	W	19930727		
OS	MARPAT 120:134509				
AB	The title compds., 2-(imidazolyl)-5-pyrimidinol or 2-(thiazolyl)-5-pyrimidinol or 2-(oxazolyl)-5-pyrimidinol derivs. I (R1-R4 = hydrogen, alkyl, etc.; X = nitrogen, sulfur, oxygen) and their uses as inflammation inhibitors are claimed. I are 5-lipoxygenase and cyclooxygenase inhibitors. For example, 2,6-di-tert-butyl-2-(2-hydroxy-5-methyl-1H-imidazol-4-yl)-5-pyrimidinol (II) was prepared in several steps.				
IT	187112-44-3P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as inflammation inhibitor)				
RN	187112-44-3 CAPLUS				
CN	2H-Imidazol-2-one, 4-[4,6-bis(1,1-dimethylethyl)-5-hydroxy-2-pyrimidinyl]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)				



10/827,294

=> => d his

(FILE 'HOME' ENTERED AT 14:40:34 ON 26 FEB 2007)

FILE 'REGISTRY' ENTERED AT 14:40:43 ON 26 FEB 2007

L1               STRUCTURE UPLOADED  
L2               14 S L1 SSS SAM  
L3               STRUCTURE UPLOADED  
L4               10 S L3 SSS SAM  
L5               724 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:45:05 ON 26 FEB 2007

L6               9 S L5

FILE 'CAOLD' ENTERED AT 14:47:49 ON 26 FEB 2007

=> s 15

L7               0 L5

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

225.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.02

STN INTERNATIONAL LOGOFF AT 14:48:03 ON 26 FEB 2007